249 results
Page 2 of 13
8-K
EX-10.1
8gkjdmi9si7a9 l0
19 Mar 21
Changes in Control of Registrant
5:23pm
424B5
pci5ayb
16 Feb 21
Prospectus supplement for primary offering
4:49pm
424B5
7jbju
16 Feb 21
Prospectus supplement for primary offering
4:46pm
8-K
EX-10.1
r57 qy33s
25 Jan 21
Caladrius Biosciences Announces $25.0 Million Private Placement
4:01pm
8-K
EX-10.1
qke erkqcajdimtjg
10 Jul 20
Entry into a Material Definitive Agreement
4:41pm
424B5
irw5fmzd8
26 May 20
Prospectus supplement for primary offering
4:02pm
8-K
EX-10.1
7ly83wo10j2oxb
26 May 20
Caladrius Biosciences Announces $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
8:02am
8-K
EX-10.2
chlnygmwm
26 May 20
Caladrius Biosciences Announces $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
8:02am
8-K
EX-5.1
nqb 2caws
26 May 20
Caladrius Biosciences Announces $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
8:02am
424B5
xx8u5f962 dl
27 Apr 20
Prospectus supplement for primary offering
7:30am
8-K
EX-5.1
13qu0gv
24 Apr 20
Caladrius Biosciences Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:02pm
8-K
EX-10.2
hzvhyns4r2olm45f4s
24 Apr 20
Caladrius Biosciences Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:02pm
8-K
EX-10.1
kx0 ouxebqq4
24 Apr 20
Caladrius Biosciences Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:02pm
8-K
EX-99.1
9v97dg
18 Nov 19
Caladrius Biosciences Reports Positive Results for CLBS16 from the ESCaPE-CMD Trial at American Heart Association Scientific Sessions 2019
6:21am